Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessU.S. allocates $3.2 billion for COVID-19 pills and other viruses’ treatments

U.S. allocates $3.2 billion for COVID-19 pills and other viruses’ treatments

Add to Favorite
Added to Favorite

 

 

On Thursday, at a White House briefing, Dr. Anthony Fauci, the country’s leading infectious diseases expert said that a new program by the U.S. will invest $3.2 billion to accelerate the process of developing pills that can treat viruses such as COVID-19 and many more dangerous viruses.

 

He mentioned that there were few treatments for many viruses that have the potential of developing into a pandemic. It would be good to be better prepared in the future if viruses such as Ebola, Dengue, West Nile or Middle East respiratory syndrome become widespread. But he reiterated that vaccines were the “centerpiece of our arsenal.”

 

To date, the U.S. has allowed the use of remdesivir, an anti-viral drug to treat COVID-19. It has also approved emergency use of three antibody combinations that makes the body’s immune system fight against the virus. These drugs have to be taken under medical supervision. However, health experts feel that a pill that can be taken patients who exhibit initial symptoms would be both convenient and helpful.

 

Initial research to make pills by drug makers has started but results will take several months. By disbursing additional funds, the government hopes to accelerate the development and manufacturing process of the private pharma involved in this endeavor.

 

Merck has been experimenting with a drug called molnupiravir. Large study results are expected by fall. Initial results indicate that the drug could reduce the risk of hospitalization, if used early in the infectious stage. It works by preventing the coronavirus from replicating easily. However, it had no effect on those who had already been hospitalized due to COVID-19.

 

Merck is not the only pharmaceutical company to research on antiviral pills. Pfizer, Roche, and AstraZeneca are three other large companies that are conducted research and looking to manufacture a pop in pill.

 

The latest round of funding by the US government for antiviral pills is not only expected to accelerate research but also act as a stockpile as scientists have said that there’s no timeline on when COVID-19 will no longer be a part of the infections that affect humans. However, they hope that vaccines, pills, and booster shots will weaken the virus to make it more manageable in future.

Photo-

Author NIAID

Subscribe to get Latest News Updates

Latest News

You may like more
more

Advance Auto Parts Downgraded to Sell Amid Earnings Miss and Weak Outlook

CFRA analysts downgraded Advance Auto Parts (NYSE:AAP) from Hold...

Guggenheim Reiterates Buy Rating on Cabaletta Bio Amid Promising Data

Guggenheim analysts reaffirmed a Buy rating and a $23...

Goldman Sachs Initiates Neutral Coverage on Doximity, Highlights Balanced Growth Potential

Goldman Sachs analysts initiated coverage on Doximity (NYSE:DOCS) with...